The brain-penetrant oral selective estrogen receptor degrader SIM0270 exhibited a favorable safety profile and early signals of antitumor activity in patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer, including those with ESR1 mutations.
The introduction of tucatinib to ado-trastuzumab emtansine significantly improved progression-free survival vs placebo plus T-DM1 in patients with previously treated HER2-positive metastatic breast cancer.
The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C mutations.
Findings from a systematic review on the efficacy of bispecific antibodies were presented during the 20th International Myeloma Society Annual Meeting.
Combining sintilimab and axitinib led to tumor shrinkage and a tolerable safety profile in patients with advanced FH-deficient renal cell carcinoma.
At the AACR 2023 Annual Meeting, a presentation revealed that people with colorectal cancer and African ancestry are less likely to be candidates for targeted therapy.
Tisagenlecleucel reinfusion shows promise as as an effective bridge to hematopoietic stem cell transplantation in pediatric B-cell acute lymphoblastic leukemia.
Final overall survival data from two arms of the phase 3 IMvigor130 trial display the potential for atezolizumab in addition to chemotherapy for patients with urothelial carcinoma.
SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab, showed early evidence of efficacy in patients with metastatic pancreatic ductal adenocarcinoma.
Treatment with olutasidenib induced durable remissions and a manageable adverse event profile in patients with relapsed/refractory acute myeloid leukemia who harbor IDH1 mutations.
A phase 1/2 trial has revealed the promise of using zilovertamab plus ibrutinib for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia.
Ribociclib combined with endocrine therapy adds survival benefit when given to patients with hormone receptor–positive/HER2-negative advanced breast cancer with visceral metastases.
The phase 2 Neo-KAN study revealed neoadjuvant adagrasib alone or in combination with nivolumab may improve pathologic complete response rates in patients with resectable, KRAS G12C–mutated non–small cell lung cancer.
Results from a phase 3 study of pembrolizumab and nadofaragene firadenovec in patients with BCG-unresponsive non–muscle invasive bladder cancer suggests that immune checkpoint inhibitors have synergy with antibody drug conjugates.
Prospective, real-world outcomes study looks to examine the efficacy and safety of afatinib in patients with advanced or metastatic solid tumors with NRG1 gene fusions.
Results from the RELATIVITY-047 trial showed improved progression-free survival for patients with advanced melanoma who received nivolumab plus relatlimab.
According to , results from a phase 1 study support that on-target magrolimab-mediated anemia is manageable in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.